Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Pharmacokinetically Targeted Intravenous Busulfan Combined with Fludarabine (BuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Hematopoietic Cell Transplant: Pretransplant Predictors of Outcomes.

Janelle Perkins, PharmD, Jongphil Kim, PhD, Claudio Anasetti, MD, Mohamed A Kharfan-Dabaja, MD, Ernesto Ayala, MD, Lia Perez, MD, Hugo Fernandez, MD, Karen Fancher, PharmD, Cheryl Tate, PharmD, Teresa Field, MD

Blood (2009) 114 (22): 3347.

https://doi.org/10.1182/blood.V114.22.3347.3347

Published: 2009

Journal Articles

Administration of Rituximab 375 Mg/m2 on Days +1 and +8 after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) Regimens for Patients with Advanced CD20+ Lymphoid Malignancies

Mohamed A Kharfan-Dabaja, MD, Cheryl Tate, Janelle Perkins, Teresa Field, Hugo F. Fernandez, Melissa Alsina, Ernesto Ayala, Jyotishankar Raychaudhuri, Lia Perez, J. Leonel Ochoa-Bayona, Linda Brand, Javier Pinilla-Ibarz, Eduardo Sotomayor, Dan Sullivan, Claudio Anasetti

Blood (2008) 112 (11): 4323.

https://doi.org/10.1182/blood.V112.11.4323.4323

Published: 2008

Journal Articles

Administration of Rituximab Is Feasible and Does Not Affect Engraftment of Allograft Recipients with Advanced CD20+ Malignancies.

Mohamed A. Kharfan-Dabaja, MD, Cheryl Tate, PharmD, Janelle Perkins, PhD, Hugo F. Fernandez, MD, Teresa Field, MD, Ernesto Ayala, MD, Lia Perez, MD, Jyotishankar Raychaudhuri, MD, Melissa Alsina, MD, Dan Sullivan, MD, Linda Brand, RN, William Poling, PhD, Claudio Anasetti, MD

Blood (2007) 110 (11): 3016.

https://doi.org/10.1182/blood.V110.11.3016.3016

Published: 2007

Journal Articles

Busulfan Area-under-the-Curve Finding Study within a Busulfan/Fludarabine (BuFlu) Conditioning Regimen before Allogeneic Hematopoietic Cell Transplantation (HCT).

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Melissa Alsina, MD, Ernesto Ayala, MD, Karen Fancher, PharmD, Hugo F. Fernandez, MD, Dawn Garrett, LPN, William Janssen, PhD, Mohamed Kharfan-Dabaja, MD, Lia Perez, MD, Daniel Sullivan, MD, Cheryl Tate, PharmD, Claudio Anasetti, MD

Blood (2006) 108 (11): 2939.

https://doi.org/10.1182/blood.V108.11.2939.2939

Published: 2006

Journal Articles

Targeted Intravenous Busulfan Combined with Fludarabine (tBuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Stem Cell Transplant: Early Results of Low Treatment Related Mortality.

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Melissa Alsina, MD, Ernesto Ayala, MD, Karen Fancher, PharmD, William Janssen, PhD, Lia Perez, MD, Daniel Sullivan, MD, Cheryl Tate, PharmD, Claudio Anasetti, MD

Blood (2005) 106 (11): 1759.

https://doi.org/10.1182/blood.V106.11.1759.1759

Published: 2005

NARROW

Pharmacokinetically Targeted Intravenous Busulfan Combined with Fludarabine (BuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Hematopoietic Cell Transplant: Pretransplant Predictors of Outcomes.

Administration of Rituximab 375 Mg/m2 on Days +1 and +8 after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) Regimens for Patients with Advanced CD20+ Lymphoid Malignancies

Administration of Rituximab Is Feasible and Does Not Affect Engraftment of Allograft Recipients with Advanced CD20+ Malignancies.

Busulfan Area-under-the-Curve Finding Study within a Busulfan/Fludarabine (BuFlu) Conditioning Regimen before Allogeneic Hematopoietic Cell Transplantation (HCT).

Targeted Intravenous Busulfan Combined with Fludarabine (tBuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Stem Cell Transplant: Early Results of Low Treatment Related Mortality.

Email alerts

ASH Publications

American Society of Hematology

Pharmacokinetically Targeted Intravenous Busulfan Combined with Fludarabine (BuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Hematopoietic Cell Transplant: Pretransplant Predictors of Outcomes.

Administration of Rituximab 375 Mg/m2 on Days +1 and +8 after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) Regimens for Patients with Advanced CD20+ Lymphoid Malignancies

Administration of Rituximab Is Feasible and Does Not Affect Engraftment of Allograft Recipients with Advanced CD20+ Malignancies.

Busulfan Area-under-the-Curve Finding Study within a Busulfan/Fludarabine (BuFlu) Conditioning Regimen before Allogeneic Hematopoietic Cell Transplantation (HCT).

Targeted Intravenous Busulfan Combined with Fludarabine (tBuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Stem Cell Transplant: Early Results of Low Treatment Related Mortality.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only